Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiretroviral therapy
protease inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2003
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AE08
|
| gptkbp:brand |
gptkb:Reyataz
|
| gptkbp:CASNumber |
198904-31-3
|
| gptkbp:category |
antiviral drug
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugInteraction |
gptkb:proton_pump_inhibitors
gptkb:rifampin statins |
| gptkbp:eliminationHalfLife |
6.5 hours
|
| gptkbp:hasMolecularFormula |
C38H52N6O7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atazanavir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 protease
|
| gptkbp:metabolism |
liver
|
| gptkbp:patentExpired |
yes
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
86%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache jaundice rash hyperbilirubinemia |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:J05AE
|
| gptkbp:bfsLayer |
6
|